Generic Name and Formulations:
Hydroquinone 4%; crm; contains sunscreens, sulfites.
- PPI, H2RA Use With Pazopanib Does Not Affect PFS, OS in Renal Cell Carcinoma
- Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer
- Tumor-treating Fields Do Not Negatively Affect Health-related QoL
- Topical Steroid Medications
- Wound Care Products
- Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma Treatment Regimens
Indications for LUSTRA-AF:
UV-induced skin dyschromia and discoloration due to hormonal changes or skin trauma.
Apply to affected areas twice daily. Discontinue if lightening effect does not occur after 2 months.
Do skin sensitivity test before use; do not use if itching, vesicle formation or excessive inflammation occurs. Avoid sun and UV light. Not for use as a sunscreen. Avoid eyes. Pregnancy (Cat.C). Nursing mothers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma